Iolyx Therapeutics Raises $15 Million Series B to Advance Immuno-Ophthalmology Pipeline
Iolyx Therapeutics, the California‑based clinical‑stage biotechnology company focused on developing targeted immuno‑ophthalmology therapies, has raised $15 million in a Series B funding round to accelerate its pipeline of treatments for ocular inflammation and autoimmune‑related eye diseases. The financing, announced in late 2025, coincided with a strategic development and commercialization agreement with global ophthalmic specialty company Laboratoires Théa that could bring up to $280 million in milestones and royalties to support late‑stage development and commercialization efforts.
The Series B round was led by Frazier Life Sciences, a life sciences venture capital firm that specializes in backing clinical‑stage biopharmaceutical companies with differentiated therapeutic programs. Frazier’s leadership in the financing reflects strong investor confidence in Iolyx’s scientific approach and clinical progress, particularly with its lead candidate, ILYX‑002, which showed promising results in Phase 2 testing for autoimmune‑associated dry eye disease.
Participation in the Series B also came from GC&H, a private investment firm known for supporting healthcare and pharmaceutical innovation alongside established venture capital partners. Together, these investors are expected to provide both capital and strategic insights as Iolyx advances its clinical and regulatory agenda across multiple therapeutic areas.
Iolyx’s Series B funding will help underwrite continued development of ILYX‑002 through pivotal studies, including planned Phase 3 trials for autoimmune dry eye disease, as well as expansion of its pipeline into autoimmune‑associated retinal conditions. This broader focus on the back of the eye represents a strategic evolution of the company’s immuno‑ophthalmology platform, which aims to address inflammatory and autoimmune drivers at both the ocular surface and deeper retinal tissues.
The announcement of the financing was paired with a strategic license and development agreement with Laboratoires Théa, through its subsidiary Théa Open Innovation, under which Iolyx granted exclusive worldwide rights (excluding Asia) to develop and commercialize ILYX‑002 for ocular surface diseases. In exchange, Iolyx is positioned to receive up to $280 million in potential clinical, regulatory, and commercial milestones, tiered royalties of up to 21 % on net sales, and reimbursement of research and development expenses, providing a strong commercial foundation for the program.
Under the terms of the agreement, Théa will assume primary responsibility for Phase 3 clinical trial execution and regulatory submissions across its designated territories, while Iolyx retains responsibility for trial design and manufacturing. Once approved, Théa will lead commercialization activities including sales, marketing, and market access, leveraging its global presence in eye care.
“Partnering with Théa positions ILYX‑002 to move rapidly into pivotal studies and, if approved, to patients worldwide,” said Elizabeth Jeffords, Chief Executive Officer and President of Iolyx Therapeutics. Jeffords emphasized that combining Iolyx’s expertise in immune‑ophthalmology with Théa’s late‑stage development and commercial scale creates the synergy needed to deliver new therapies for patients with unmet needs.
The Phase 2 clinical trial of ILYX‑002 reported encouraging results, including statistically significant improvements in corneal staining in patients with autoimmune‑associated dry eye disease, which has historically lacked safe and effective treatment options. These data provided a compelling rationale for advancing to Phase 3 and for expanding the program into posterior eye diseases through the newly raised capital.
In addition to supporting pivotal studies, the Series B funding will enable Iolyx to broaden its research efforts into autoimmune‑associated retinal diseases, where inflammation and immune dysregulation play critical roles in vision‑threatening conditions such as uveitis and other inflammatory retinal disorders. By building on its RIPK1 inhibition platform, Iolyx aims to create therapies that address unmet medical needs with targeted, locally administered formulations.
The combined impact of the Series B financing and the strategic collaboration with Théa positions Iolyx for the next stage of growth as it navigates clinical development, regulatory engagements, and eventual commercialization. With a clear path to Phase 3 readiness and expanded therapeutic ambitions, the company is poised to make meaningful advances in immuno‑ophthalmology treatment paradigms.
As the company moves forward, investor support from Frazier Life Sciences and GC&H — along with commercial momentum enabled by the Théa agreement — underscores the growing enthusiasm for targeted ocular therapies that combine scientific rigor with practical patient impact. The funding and partnership are expected to accelerate Iolyx’s efforts to bring new treatment options to people affected by autoimmune and inflammatory eye diseases worldwide.
